Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Metastatic Breast Cancer (MBC) Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. age\>=18years~2. Eastern Cooperative Oncology Group (ECOG) performance status (PS) \<=2 and a life expectancy \>= 12 weeks;~3. histological-proven, HER-2 negative measurable stage IV disease;~4. exposure to anthracyclines, taxanes either in the neoadjuvant/adjuvant or in the metastatic setting and had documented disease progression after the firstline or secondline treatment~5. Patients previously treated with radiotherapy were eligible for the study, provided that measurable disease existed outside the radiation field.~6. At least 3 weeks from the prior chemotherapy or radiotherapy. At least 2 weeks from the prior endocrine therapy.~Exclusion Criteria:~1. Patients with active infection or other serious underlying medical conditions~2. Patients had prior treatment with 5-FU infusion and/or oxaliplatin therapy~3. Inadequate bone marrow, liver, renal, medullary, and cardiac functions~4. Evidence of spinal cord compression or brain metastasis~5. History of another malignancy within the last five years except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix or a contralateral breast cancer~6. Pregnant or lactating women~7. Serious uncontrolled intercurrent infection~8. History or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding~9. Serious non-bleeding wound, peptic ulcer or bone fracture~10. Prior dihypopyrimidine dehydrogenase deficiency~11. Hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanlised antibodies

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Avastin + mFOLFOX6 (Type: EXPERIMENTAL): Avastin plus FOLFOX6 regimen in the management of her-2 negative breast cancer patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).